Viewpoint: CancerLinQ Enrolls Practices, Prepares to Usher in 'Big Data Oncology' Era
View web version
You are receiving this newsletter as a promotional effort on behalf of CancerTherapyAdvisor.com.
Click here to sign up to receive these newsletters on a regular basis.

The original version of this drug showcase misspelled Kyprolis. The error has been corrected in this version.

Drug Showcase
KYPROLIS (carfilzomib) for Refractory Multiple Myeloma
This slideshow reviews drug information for KYPROLIS (carfilzomib), indicated for refractory multiple myeloma.
Viewpoint
CancerLinQTM Enrolls Practices, Prepares to Usher in 'Big Data Oncology' Era
By
Publishers Alliance
Multiple myeloma: Optimal management and long-term disease control
By Priya Sriskandarajah, Faith E. Davies

For more on the latest research and developments in oncology, visit our News section.

Latest News
Bevacizumab Plus Temozolomide Produces Low Response in Newly-Diagnosed Glioblastoma
Abiraterone Acetate Prolongs Survival in Metastatic Prostate Cancer
Standard-Dose vs. High-Dose Chemoradiotherapy With, Without Cetuximab for Lung Cancer
Contraceptive Use Linked to Higher Risk of Glioma

Want to receive emails specific to your profession and specialty? Click here to complete your profile.





Subscribe
If you were sent this by a colleague and wish to subscribe to Weekly highlights, please click here.

Unsubscribe
To unsubscribe from the Weekly Highlights click here.
To manage your entire Cancer Therapy Advisor profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All Cancer Therapy Advisor newsletters are sent from the domain "email.cancertherapyadvisor.com". When configuring e-mail or spam filter rules, please use this domain name.

© 2015 Haymarket Media Inc
114 West 26th St 4th floor
New York, NY 10001